Bristol-Meyers Crushes Q2 via Overseas Hep C Med Sales

Thursday, July 23, 2015

Source: FiercePharma

Here's an earnings trend-buster: Bristol-Myers Squibb ($BMY) trounced expectations for the second quarter and hiked its full-year sales forecast by more than $1 billion. And to do that, the company overcame a couple of big challenges that took the wind out of its Big Pharma rivals: Generic competition for one of its former blockbusters, and a major hit from the strong dollar.

View All News »